Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase 3b CONSIGN trial

被引：0
|
作者：
Kasper, S. [1 ]
van Cutsem, E. [2 ]
Ciardello, F. [3 ]
Ychou, M. [4 ]
Seitz, J. -F [5 ]
Hofheinz, R. -D [6 ]
Arriaga, Y. E. [7 ]
Verma, U. [7 ]
Garcia-Carbonero, R. [8 ]
Grothey, A. [9 ]
Miriyala, A. [10 ]
Kalmus, J. [10 ]
Kappeler, C. [10 ]
Falcone, A. [11 ]
Zaniboni, A. [12 ]
机构：
[1] Univ Klinikum Essen, Westdeutsch Tumorzentrum, Essen, Germany
[2] Univ Hosp Leuven, Leuven, Belgium
[3] Univ Naples 2, Naples, Italy
[4] Inst Reg Canc Montpellier, Montpellier, France
[5] Aix Marseille Univ, Marseille, France
[6] Univ Klin Mannheim, Mannheim, Germany
[7] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[8] Hosp Univ Doce Octubre, Madrid, Spain
[9] Mayo Clin, Rochester, MN USA
[10] Bayer Pharma AG, Berlin, Germany
[11] Univ Pisa, Pisa, Italy
[12] Fdn Poliambulanza, Brescia, Italy
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P304
引用
收藏
页码：94 / 95
页数：2
相关论文
共 50 条
  • [41] Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
    Cunningham, David
    Lang, Istvan
    Marcuello, Eugenio
    Lorusso, Vito
    Ocvirk, Janja
    Shin, Dong Bok
    Jonker, Derek
    Osborne, Stuart
    Andre, Niko
    Waterkamp, Daniel
    Saunders, Mark P.
    LANCET ONCOLOGY, 2013, 14 (11): : 1077 - 1085
  • [42] Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial
    Carcao, M.
    Zak, M.
    Karim, F. Abdul
    Hanabusa, H.
    Kearney, S.
    Lu, M. -Y.
    Persson, P.
    Rangarajan, S.
    Santagostino, E.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 (08) : 1521 - 1529
  • [43] Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial
    Teufel, Michael
    Schwenke, Susanne
    Seidel, Henrik
    Beckmann, Georg
    Reischl, Joachim
    Vonk, Richardus
    Lenz, Heinz-Josef
    Tabernero, Josep
    Siena, Salvatore
    Grothey, Axel
    Van Cutsem, Eric
    Jeffers, Michael
    Wilhelm, Scott
    Wagner, Andrea
    Laurent, Dirk
    Kobina, Svetlana
    Rutstein, Mark Daniel
    Wirapati, Pratyaksha
    Guinney, Justin
    Tejpar, Sabine
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [44] AN OPEN-LABEL MULTICENTER PHASE II TRIAL OF AVISCUMINE IN PREVIOUSLY TREATED PATIENTS WITH UNRESECTABLE STAGE IV METASTATIC MELANOMA
    Uwe, Trefzer
    Ralf, Gutzmer
    Tabea, Wilhelm
    Florian, Schenck
    Katharina, Kaehler C.
    Volkmar, Jacobi
    Klaus, Witthohn
    Hans, Lentzen
    Peter, Mohr
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S7 - S7
  • [45] A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer
    Hickish, Tamas
    Cassidy, Jim
    Propper, David
    Chau, Ian
    Falk, Stephen
    Ford, Hugo
    Iveson, Tim
    Braun, Michael
    Potter, Vanessa
    Macpherson, Iain R.
    Finnigan, Helen
    Lee, Chooi
    Jones, Hilary
    Harrison, Mark
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (18) : 3136 - 3144
  • [46] Dasatinib (D) in previously treated metastatic colorectal cancer (mCRC) patients: A phase II trial of the University of Chicago phase II consortium
    Sharma, M.
    Wroblewski, K.
    Kozloff, M.
    Modi, S. S.
    Sleckman, B. G.
    Taber, D.
    Vokes, E. E.
    Stadler, W. M.
    Polite, B. N.
    Kindler, H. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [47] Analysis of single-nucleotide polymorphisms (SNPs) in the phase 3 CORRECT trial of regorafenib vs placebo in patients with metastatic colorectal cancer (mCRC)
    Lambrechts, D.
    Koechert, K.
    Schulz, A.
    Vonk, R.
    Rutstein, M.
    Kobina, S.
    Grothey, A.
    Van Cutsem, E.
    Teufel, M.
    ANNALS OF ONCOLOGY, 2016, 27 : 102 - 102
  • [48] Subgroup analysis of patients enrolled in the United States in the CORRECT phase 3 trial of the multikinase inhibitor regorafenib (REG) in metastatic colorectal cancer (mCRC).
    Lenz, Heinz-Josef
    Van Cutsem, Eric
    Verma, Udit N.
    Saltzman, Marc
    Fuloria, Jyotsna
    Khojasteh, Ali
    Wiesenfeld, Martin
    Cihon, Frank
    Wagner, Andrea
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [49] Subgroup analysis of patients enrolled in the United States in the CORRECT phase 3 trial of the multikinase inhibitor regorafenib (REG) in metastatic colorectal cancer (mCRC).
    Kim, George P.
    Van Cutsem, Eric
    Lenz, Heinz-Josef
    Verma, Udit N.
    Saltzman, Marc
    Fuloria, Jyotsna
    Khojasteh, Ali
    Wiesenfeld, Martin
    Cihon, Frank
    Wagner, Andrea
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [50] Hand-foot skin reaction (HFSR) and outcomes in the phase 3 CORRECT trial of regorafenib for metastatic colorectal cancer (mCRC).
    Grothey, Axel
    Huang, Liping
    Wagner, Andrea
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345